349 related articles for article (PubMed ID: 35013218)
21. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
22. Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma.
Borankova K; Krchniakova M; Leck LYW; Kubistova A; Neradil J; Jansson PJ; Hogarty MD; Skoda J
Cell Death Dis; 2023 Nov; 14(11):747. PubMed ID: 37973789
[TBL] [Abstract][Full Text] [Related]
23. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling.
Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W
Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277
[TBL] [Abstract][Full Text] [Related]
24. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
Chipumuro E; Marco E; Christensen CL; Kwiatkowski N; Zhang T; Hatheway CM; Abraham BJ; Sharma B; Yeung C; Altabef A; Perez-Atayde A; Wong KK; Yuan GC; Gray NS; Young RA; George RE
Cell; 2014 Nov; 159(5):1126-1139. PubMed ID: 25416950
[TBL] [Abstract][Full Text] [Related]
25. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
26. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
Bugide S; Gupta R; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301901
[TBL] [Abstract][Full Text] [Related]
27. MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.
Salib A; Jayatilleke N; Seneviratne JA; Mayoh C; De Preter K; Speleman F; Cheung BB; Carter DR; Marshall GM
Oncogene; 2024 Jan; 43(5):363-377. PubMed ID: 38049564
[TBL] [Abstract][Full Text] [Related]
28. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
29. EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia.
Kosalai ST; Morsy MHA; Papakonstantinou N; Mansouri L; Stavroyianni N; Kanduri C; Stamatopoulos K; Rosenquist R; Kanduri M
Epigenetics; 2019 Nov; 14(11):1125-1140. PubMed ID: 31216925
[TBL] [Abstract][Full Text] [Related]
30. EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.
Wee ZN; Li Z; Lee PL; Lee ST; Lim YP; Yu Q
Cell Rep; 2014 Jul; 8(1):204-16. PubMed ID: 24953652
[TBL] [Abstract][Full Text] [Related]
31. FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells.
Rellinger EJ; Craig BT; Alvarez AL; Dusek HL; Kim KW; Qiao J; Chung DH
Surgery; 2017 Mar; 161(3):747-752. PubMed ID: 27919448
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high-MYC medulloblastoma.
Natsumeda M; Liu Y; Nakata S; Miyahara H; Hanaford A; Ahsan S; Stearns D; Skuli N; Kahlert UD; Raabe EH; Rodriguez FJ; Eberhart CG
Neuropathology; 2019 Apr; 39(2):71-77. PubMed ID: 30632221
[TBL] [Abstract][Full Text] [Related]
33. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.
Vaughan L; Clarke PA; Barker K; Chanthery Y; Gustafson CW; Tucker E; Renshaw J; Raynaud F; Li X; Burke R; Jamin Y; Robinson SP; Pearson A; Maira M; Weiss WA; Workman P; Chesler L
Oncotarget; 2016 Sep; 7(36):57525-57544. PubMed ID: 27438153
[TBL] [Abstract][Full Text] [Related]
35. YM155 inhibits neuroblastoma growth through degradation of MYCN: A new role as a USP7 inhibitor.
Li X; Yang F; He N; Zhang M; Lv Y; Yu Y; Dong Q; Hou X; Hao Y; An Z; Zhang H; Yang Z; Zhai H; Guo D; Cao Z; Jiang VC; Chen Y
Eur J Pharm Sci; 2023 Feb; 181():106343. PubMed ID: 36436754
[TBL] [Abstract][Full Text] [Related]
36. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.
Tian X; Xu J; Fletcher C; Hornick JL; Dorfman DM
Mod Pathol; 2018 Apr; 31(4):553-561. PubMed ID: 29327713
[TBL] [Abstract][Full Text] [Related]
37. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
38. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.
Otto T; Horn S; Brockmann M; Eilers U; Schüttrumpf L; Popov N; Kenney AM; Schulte JH; Beijersbergen R; Christiansen H; Berwanger B; Eilers M
Cancer Cell; 2009 Jan; 15(1):67-78. PubMed ID: 19111882
[TBL] [Abstract][Full Text] [Related]
39. Methyltransferase-independent function of enhancer of zeste homologue 2 maintains tumorigenicity induced by human oncogenic papillomavirus and polyomavirus.
Khattri M; Amako Y; Gibbs JR; Collura JL; Arora R; Harold A; Li MY; Harms PW; Ezhkova E; Shuda M
Tumour Virus Res; 2023 Dec; 16():200264. PubMed ID: 37244352
[TBL] [Abstract][Full Text] [Related]
40. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
